聶德權:視乎接種第三針新冠疫苗情況再決定是否擴展至全民接種
對於合資格特定羣組可預約接種第三劑新冠疫苗,公務員事務局局長聶德權出席《無線電視》節目時表示,會視乎未來數週接種情況等,決定是否擴展至全民接種,又指暫難評價預約接種的反應好壞,因爲市民可取「即日籌」。
被問到若反應冷淡,會否考慮調整「疫苗氣泡」,如進入C、D類食肆等員工及食客要接種第三針,聶德權稱,現階段應令市民明白第三針的重要性及提供誘因,如打第三針對政府僱員來說,之前在接種第一針及第二針時,安排有一日疫苗假期,他覺得第三針有同樣安排是很合理的做法,會看情況推行時再作公佈。
至於是否接種第三針纔可往內地通關,聶德權認爲,將來去內地要求一定是要接種疫苗,但推行的時候要求如何,屆時纔會清楚。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.